Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | MicrobiomeTrials← Back to trialsNCT05766371
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-12-15Est. Completion: 2027-05-31
Enrollment target: 48 participants Locations- University of California, San Francisco, San Francisco, California, United States
Other microbiome trials you might be interested in
Hormone-refractory Prostate Cancer
The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), fol…
Orange, United StatesEst. completion Sep 29, 2027
Prostate Cancer Metastatic
This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metas…
Redwood City, United StatesEst. completion Oct 2028